Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02255032 · ClinicalTrials.gov registry record · Phase 2
Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis
A Phase 2 study of Uveitis and Macular Edema, sponsored by Clearside Biomedical.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 11
- Study locations
NCT02255032: Completed Phase 2 study of Uveitis and Macular Edema, sponsored by Clearside Biomedical.
NCT02255032 is a Phase 2 study of Uveitis and Macular Edema that has completed, run by Clearside Biomedical. The registered enrollment target is 22 participants, below the 616-participant average among 19 other Uveitis trials with a reported enrollment target (96% lower). The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02255032, a Phase 2 study of Uveitis and Macular Edema, has completed, sponsored by Clearside Biomedical.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 11
- Study locations
Study Summary
The study is designed to evaluate the safety and efficacy of triamcinolone acetonide, CLS-TA, in subjects with macular edema following non-infectious uveitis. A single suprachoroidal injection of one of two doses of CLS-TA will each be evaluated in subjects with macular edema following non-infectious uveitis.
Conditions Studied
Interventions
- DRUG 4 mg CLS-TA
- DRUG 0.8 mg CLS-TA
Study Locations (11)
Massachusetts
- - Boston
- - Waltham
Florida
- - Miami
Georgia
- - Atlanta
Illinois
- - Chicago
Nebraska
- - Omaha
New York
- - New York
North Carolina
- - Winston-Salem
North Dakota
- - Fargo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
What the finished NCT02255032 record still lists
NCT02255032 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 616-participant average among 19 other Uveitis trials with a reported enrollment target (96% lower).
The record links to 6 conditions, with Uveitis appearing as the primary indexed condition, and to 2 interventions - of which 4 mg CLS-TA is the first listed.
NCT02255032 lists 11 locations in 10 states (Massachusetts, Florida, Georgia).
Frequently Asked Questions
What is clinical trial NCT02255032 about?
NCT02255032 is a clinical study titled "Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis". The study is designed to evaluate the safety and efficacy of triamcinolone acetonide, CLS-TA, in subjects with macular edema following non-infectious uveitis. A single suprachoroidal injection of one of two doses of CLS-TA will each be evaluated in subjects with macular edema following non-infectiou...
What is the current status of trial NCT02255032?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2014-10. Estimated completion is 2016-01.
What conditions does trial NCT02255032 study?
This clinical trial studies the following conditions: Uveitis, Macular Edema, Uveitis, Posterior, Uveitis, Intermediate, Uveitis, Anterior.
What interventions are being tested in trial NCT02255032?
The interventions under investigation include: 4 mg CLS-TA (DRUG), 0.8 mg CLS-TA (DRUG).
Who is sponsoring clinical trial NCT02255032?
This trial is sponsored by Clearside Biomedical, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02255032 being conducted?
This trial has 11 study locations across Florida, Georgia, Illinois, Massachusetts, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02255032's enrollment target sits among peer trials
22 18th of 19 higher than 2 of 19 other Uveitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Uveitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study)
COMPLETED · Phase 2
-
RChildUV:Study on Non-infectious Chronic Uveitis in Pediatric Age
RECRUITING
-
Genetics of Uveitis
RECRUITING
-
Analysis of Anterior Chamber Inflammation by Optical Coherence Tomography
RECRUITING
-
Ocular Pathogen and Transcriptome Investigation Using Comprehensive Sequencing
RECRUITING · NA
-
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia